XOMA Royalty Down Nearly 11%, on Pace for Largest Percent Decrease Since January 2023 -- Data Talk

Dow JonesOct 30 11:18 ET

XOMA Royalty Significantly Expands Its Royalty and Milestone Portfolio With the Addition of Over 60 Early-Stage Programs From Twist Bioscience

Globe NewswireOct 22 08:00 ET

While Shareholders of XOMA Royalty (NASDAQ:XOMA) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate

Simply Wall StSep 27 06:01 ET

XOMA Corp - 8.375% DP PFD B Declares $0.5234 Dividend

Seeking AlphaSep 23 08:49 ET

Express News | XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones

BenzingaSep 23 06:34 ET

Zevra's MIPLYFFA (Arimoclomol) Receives Approval From U.S. Food and Drug Administration for Use in Patients With Niemann-Pick Disease Type C (NPC)

GlobeNewswireSep 23 06:30 ET